These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

138 related articles for article (PubMed ID: 16361562)

  • 1. Neamine inhibits xenografic human tumor growth and angiogenesis in athymic mice.
    Hirukawa S; Olson KA; Tsuji T; Hu GF
    Clin Cancer Res; 2005 Dec; 11(24 Pt 1):8745-52. PubMed ID: 16361562
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Neamine inhibits oral cancer progression by suppressing angiogenin-mediated angiogenesis and cancer cell proliferation.
    Kishimoto K; Yoshida S; Ibaragi S; Yoshioka N; Hu GF; Sasaki A
    Anticancer Res; 2014 May; 34(5):2113-21. PubMed ID: 24778013
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Pharmacokinetics of neamine in rats and anti-cervical cancer activity in vitro and in vivo.
    Liu Y; Zhang X; An S; Wu Y; Hu G; Wu Y
    Cancer Chemother Pharmacol; 2015 Mar; 75(3):465-74. PubMed ID: 25552400
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Neamine inhibits growth of pancreatic cancer cells in vitro and in vivo.
    Liu YP; Wu YL; Zhang XY; Hu GF; Wu YX
    J Huazhong Univ Sci Technolog Med Sci; 2016 Feb; 36(1):82-87. PubMed ID: 26838745
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Neamine inhibits prostate cancer growth by suppressing angiogenin-mediated rRNA transcription.
    Ibaragi S; Yoshioka N; Li S; Hu MG; Hirukawa S; Sadow PM; Hu GF
    Clin Cancer Res; 2009 Mar; 15(6):1981-8. PubMed ID: 19276260
    [TBL] [Abstract][Full Text] [Related]  

  • 6. A therapeutic target for prostate cancer based on angiogenin-stimulated angiogenesis and cancer cell proliferation.
    Yoshioka N; Wang L; Kishimoto K; Tsuji T; Hu GF
    Proc Natl Acad Sci U S A; 2006 Sep; 103(39):14519-24. PubMed ID: 16971483
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Angiogenin regulation by estradiol in breast tissue: tamoxifen inhibits angiogenin nuclear translocation and antiangiogenin therapy reduces breast cancer growth in vivo.
    Nilsson UW; Abrahamsson A; Dabrosin C
    Clin Cancer Res; 2010 Jul; 16(14):3659-69. PubMed ID: 20501617
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Sub-chronic 90-day toxicity of neamine in SD rats and its anti-liver cancer activity in vitro and in vivo.
    Wu Y; Feng Y; Li Y; Xu Y; Shi N; Hu GF; Wu Y
    Toxicol Appl Pharmacol; 2017 Jan; 315():50-59. PubMed ID: 27940282
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Kaposi's sarcoma-associated herpesvirus-positive primary effusion lymphoma tumor formation in NOD/SCID mice is inhibited by neomycin and neamine blocking angiogenin's nuclear translocation.
    Bottero V; Sadagopan S; Johnson KE; Dutta S; Veettil MV; Chandran B
    J Virol; 2013 Nov; 87(21):11806-20. PubMed ID: 23986578
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Suppression of uPA and uPAR attenuates angiogenin mediated angiogenesis in endothelial and glioblastoma cell lines.
    Raghu H; Lakka SS; Gondi CS; Mohanam S; Dinh DH; Gujrati M; Rao JS
    PLoS One; 2010 Aug; 5(8):e12458. PubMed ID: 20805979
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Neomycin inhibits angiogenin-induced angiogenesis.
    Hu GF
    Proc Natl Acad Sci U S A; 1998 Aug; 95(17):9791-5. PubMed ID: 9707554
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Neamine is preferential as an anti-prostate cancer reagent by inhibiting cell proliferation and angiogenesis, with lower toxicity than cis-platinum.
    Liu YP; Hu GF; Wu YX
    Oncol Lett; 2015 Jul; 10(1):137-142. PubMed ID: 26170989
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Brain-derived neurotrophic factor induces angiogenin secretion and nuclear translocation in human umbilical vein endothelial cells.
    Mori A; Nishioka Y; Yamada M; Nishibata Y; Masuda S; Tomaru U; Honma N; Moriyama T; Ishizu A
    Pathol Res Pract; 2018 Apr; 214(4):521-526. PubMed ID: 29573867
    [TBL] [Abstract][Full Text] [Related]  

  • 14. SKLB1002, a novel potent inhibitor of VEGF receptor 2 signaling, inhibits angiogenesis and tumor growth in vivo.
    Zhang S; Cao Z; Tian H; Shen G; Ma Y; Xie H; Liu Y; Zhao C; Deng S; Yang Y; Zheng R; Li W; Zhang N; Liu S; Wang W; Dai L; Shi S; Cheng L; Pan Y; Feng S; Zhao X; Deng H; Yang S; Wei Y
    Clin Cancer Res; 2011 Jul; 17(13):4439-50. PubMed ID: 21622720
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Neamine induces neuroprotection after acute ischemic stroke in type one diabetic rats.
    Ning R; Chopp M; Zacharek A; Yan T; Zhang C; Roberts C; Lu M; Chen J
    Neuroscience; 2014 Jan; 257():76-85. PubMed ID: 24211797
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Barbigerone, an isoflavone, inhibits tumor angiogenesis and human non-small-cell lung cancer xenografts growth through VEGFR2 signaling pathways.
    Li X; Wang X; Ye H; Peng A; Chen L
    Cancer Chemother Pharmacol; 2012 Sep; 70(3):425-37. PubMed ID: 22814678
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Angiogenin-induced protein kinase B/Akt activation is necessary for angiogenesis but is independent of nuclear translocation of angiogenin in HUVE cells.
    Kim HM; Kang DK; Kim HY; Kang SS; Chang SI
    Biochem Biophys Res Commun; 2007 Jan; 352(2):509-13. PubMed ID: 17125737
    [TBL] [Abstract][Full Text] [Related]  

  • 18. The chemopreventive agent oltipraz possesses potent antiangiogenic activity in vitro, ex vivo, and in vivo and inhibits tumor xenograft growth.
    Ruggeri BA; Robinson C; Angeles T; Wilkinson J; Clapper ML
    Clin Cancer Res; 2002 Jan; 8(1):267-74. PubMed ID: 11801568
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Prevention of human prostate tumor metastasis in athymic mice by antisense targeting of human angiogenin.
    Olson KA; Byers HR; Key ME; Fett JW
    Clin Cancer Res; 2001 Nov; 7(11):3598-605. PubMed ID: 11705882
    [TBL] [Abstract][Full Text] [Related]  

  • 20. YM-359445, an orally bioavailable vascular endothelial growth factor receptor-2 tyrosine kinase inhibitor, has highly potent antitumor activity against established tumors.
    Amino N; Ideyama Y; Yamano M; Kuromitsu S; Tajinda K; Samizu K; Hisamichi H; Matsuhisa A; Shirasuna K; Kudoh M; Shibasaki M
    Clin Cancer Res; 2006 Mar; 12(5):1630-8. PubMed ID: 16533791
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.